## **Trustees’ Annual Report for the period** **From 02/11/2019 Period start date To 01/11/2020 Period end date** ## **Charity name: NTM PATIENT CARE UK** ## **Charity registration number: 181372** ## **Objectives and Activities** ||SORP reference|| |---|---|---| |Summary of the purposes of
the charity as set out in its
governing document|Para 1.17|The purpose of NTM Patient Care UK is to
provide information and support to NTM
patients. We also work with Healthcare
Professional (HCP) teams to improve
understanding of patient needs, co-
ordinating and facilitating the transfer of
information in both directions between the
two.
This purpose is set out in the Constitution
as the following objectives;
Working to improve the lives of people with
non-tuberculous mycobacterial (NTM)
infection in the UK, in particular but not
exclusively by;
a) the provision of education and
information to increase understanding of
NTM in both the clinical and patient
communities.
b) the development and implementation of
a support network for NTM patient
communities.| |Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or
services identified in the
accounts.|Para 1.17 and
1.19|_Main activities for this reporting period_
_include to the following;_
a) Organisation of regular Trustee Meetings
to develop strategies for the patient
association to meet its intended goals.
b) NTM Patient Care UK has held regular
Zoom Meetings for NTM patients and
Healthcare Professionals with an interest in
NTM.
These meetings have included talks &
presentations on areas with specific
relevance to NTM patients such as physio,
pharmacy and dietetics.| |||These meetings also provide both support
and a forum for NTM patients to share and
discuss their experiences of NTM and
associated issues.
c) Development of a website to allow the
patient association to provide information
and support to NTM patients; this went live
in October 2020.
d) Engagement with NTM patients and
Healthcare Professionals (HCPs) to
develop support in the further development
of the patient association.
e) NTM Patient Care UK has continued to
raise awareness of this disease within the
medical community and actively engaged
with a number of NTM patients and their
wider support community.| |---|---|---| |Statement confirming
whether the trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit|Para 1.18|The trustees have had regard to the Charity
Commission’s guidance on public benefit.| ## **Additional information (optional)** You may choose to include further statements where relevant about: ||SORP reference|| |---|---|---| |Policy on grant making|Para 1.38|N/A| |Policy on social investment
including program related
investment|Para 1.38|N/A| |Contribution made by
volunteers|Para 1.38|N/A| |Other||N/A| ## **Achievements and Performance** ||SORP reference|| |---|---|---| |Summary of the main
achievements of the charity,
identifying the difference the
charity’s work has made to
the circumstances of its
beneficiaries and any wider
benefits to society as a
whole.|Para 1.20|Main activities for this reporting period have
included the following;
a) Provision of improved support and
information specific to NTM patients.
b) Development and implementation of a
website that provides NTM patients with a
source of information and advice specific to
their situation. This includes patient stories,
frequently asked questions, news stories,
research info, links to other information
sources as well as information on physio,
mental health and other useful info.
c) Provision of regular Zoom meetings to
provide relevant information and support
specific to NTM patients. This has
improved support available to these
patients as well as providing an excellent
opportunity for informal interaction between
NTM patients and HCPs. This interaction
has provided an improved understanding of
NTM and the patient experience within both
groups.| **Additional information (optional)** You may choose to include further statements where relevant about: |Achievements against
objectives set|Para 1.41|N/A| |---|---|---| |Performance of fundraising
activities against objectives
set|Para 1.41|N/A| |Investment performance
against objectives|Para 1.41|N/A| |Other||N/A| ## **Financial Review** |**Financial Review**||| |---|---|---| |Review of the charity’s
financial position at the end
of the period|Para 1.21|| |Statement explaining the
policy for holding reserves
stating why they are held|Para 1.22|NTM Patient Care UK has no policy for
holding reserves and a policy is not
considered necessary as the charity has
had no spending during this reporting
period.
The trustees have decided that holding
reserves is unnecessary, as during this
period the charity had no spending.| |Amount of reserves held|Para 1.22|None| |Reasons for holding zero
reserves|Para 1.22|The charity has had no spending over the
reporting period so reserves are not
considered necessary.| |Details of fund materially in
deficit|Para 1.24|N/A| |Explanation of any
uncertainties about the
charity continuing as a going
concern|Para 1.23|N/A| |**Additional information (optional)**
You may choose to include further statements|**Additional information (optional)**
You may choose to include further statements|where relevant about:| |---|---|---| |The charity’s principal
sources of funds (including
any fundraising)|Para 1.47|NTM Patient Care received a single grant
from a pharmaceutical company
(£25,000.00) in March 2020.| |Investment policy and
objectives including any
social investment policy
adopted|Para 1.46|N/A| |A description of the principal
risks facing the charity|Para 1.46|N/A| |Other||N/A| ## **Structure, Governance and Management** |Description of charity’s
trusts:||N/A| |---|---|---| |Type of governing document
(trust deed, royal charter)|Para 1.25|Constitution of the Charitable Incorporated
Organisation (CIO)| |How is the charity
constituted?
(e.g unincorporated
association, CIO)|Para 1.25|Charitable Incorporated Organisation (CIO)| |Trustee selection methods
including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trustees|Para 1.25|Trustees include founding individuals, NTM
patients and HCPs to ensure the best
representation of the needs of NTM
patients.
More details of Trustee selection is
provided in the Constitution.| ## **Additional information (optional)** You may choose to include further statements where relevant about: |Policies and procedures
adopted for the induction
and training of trustees|Para 1.51|N/A| |---|---|---| |The charity’s organisational
structure and any wider
network with which the
charity works|Para 1.51|N/A| |Relationship with any
related parties|Para 1.51|N/A| |Other||N/A| ## **Reference and Administrative details** |Charity name|**NTM Patient Care UK**| |---|---| |Other name the charity uses|**N/A**| |Registered charity number|**1181372**| |Charity’s principal address|**Royal Free London NHS Foundation Trust, Pond St,**
**Hampstead, London NW3 2QG**| ## **Names of the charity trustees who manage the charity during period of report** |1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20|**Trustee name**|**Office (if any)**|**Dates acted if not for whole year**|**Name of person (or body) entitled**
**to appoint trustee (ifany)**| |---|---|---|---|---| ||Prof Marc Lipman|Trustee||| ||Prof James Chalmers|Trustee|Resigned 29-June-2020|| ||Mr Robin Arnell|Trustee|Resigned 09-September-2020|| ||Ms Judi Bitel|Trustee|Resigned 09-September-2020|| ||Prof Michael King|Trustee|from 07-August-2020|| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| – Corporate trustees names of the directors at the date the report was approved **Director name N/A** Name of trustees holding title to property belonging to the charity |**Trustee name**|**Dates acted if not for whole year**|| |---|---|---| |**N/A**||| |||| |||| |||| |||| |||| ## **Funds held as custodian trustees on behalf of others** Description of the assets N/A held in this capacity Name and objects of the N/A charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for N/A safe custody and segregation of such assets from the charity’s own assets ## **Additional information (optional)** ## **Names and addresses of advisers (Optional information)** |**Names and addresses of advisers (Optional information)**|**Names and addresses of advisers (Optional information)**|**Names and addresses of advisers (Optional information)**| |---|---|---| |**Type of adviser**
**Name**
**Address**||| |Technical & Medical
Communications
advisor|John
Hockley|Axiom Health Ltd, 399 Station Road, Petworth, West
Sussex| |||| |||| |||| ## **Name of chief executive or names of senior staff members (Optional information)** **N/A** ## **Exemptions from disclosure** Reason for non-disclosure of key personnel details **N/A** ## **Other optional information** **N/A** ## **Declarations** **The trustees declare that they have approved the trustees’ report above.** **Signed on behalf of the charity’s trustees** **Signature(s)** Marc LipmanMarc Lipman (Oct 24, 2021 20:20 GMT+1) **Full name(s)** Prof Marc Lipman **Position (eg Secretary,** Chair **Chair, etc) Date** Oct 24, 2021 ## Trustee Annual Report-DOC 24-OCT-2021 (Period 02.11.2019 to 01.11.2020) ## Final Audit Report ## 2021-10-24 Created: 2021-10-24 By: Sarah Bryant (sarah@axiom-health.co.uk) Status: Signed Transaction ID: CBJCHBCAABAAHT-BcsFTvzhL0axpkK6S-ioFdVZWgF40 ## "Trustee Annual Report-DOC 24-OCT-2021 (Period 02.11.2019 to 01.11.2020)" History ## Document created by Sarah Bryant (sarah@axiom-health.co.uk) 2021-10-24 - 7:03:53 PM GMT- IP address: 158.172.153.1 Document emailed to Marc Lipman (marclipman@nhs.net) for signature 2021-10-24 - 7:05:42 PM GMT ## Email viewed by Marc Lipman (marclipman@nhs.net) 2021-10-24 - 7:19:41 PM GMT- IP address: 94.175.228.196 ## Document e-signed by Marc Lipman (marclipman@nhs.net) Signature Date: 2021-10-24 - 7:20:08 PM GMT - Time Source: server- IP address: 94.175.228.196 ## Agreement completed. 2021-10-24 - 7:20:08 PM GMT ||
**NTM Patient Care UK**|
**NTM Patient Care UK**|
**NTM Patient Care UK**|**No (if any)**|**CC16a**| |---|---|---|---|---|---| ||**Receipts andpayments accounts**||||| ||**For the period**
**from**|01/11/2019|**To**|01/11/2020|| ||||||| |**Section A Receipts an**|**d payments**||||| |**A1 Receipts**|**Unrestricted**
**funds**
**to the nearest**
**£**|**Restricted**
**funds**
**to the nearest £**|**Endowment**
**funds**
**to the nearest £**|**Total funds**
**to the nearest £**|| ||**25,000**|**-**|**-**|**25,000**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| |**_Sub total_**_(Gross income for_
_AR)_|

**25,000.00**|**0.00**|**0.00**|**25,000.00**|**0.00**| |**A2 Asset and investment sales,**
**(see table).**|||||| ||**-**|**-**|**-**|**-**|| ||**-**|**-**|**-**|**-**|**-**| |**_Sub total_**|
**0.00**|**0.00**|**0.00**|**0.00**|**0.00**| |**_Total receipts_**
**A3 Payments**|||||| ||**25,000.00**|**0.00**|**0.00**|**25,000.00**|**0.00**| ||||||| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| |**_Sub total_**|**0.00**|**0.00**|**0.00**|**0.00**|**0.00**| ||||||| |**A4 Asset and investment**
**purchases, (see table)**|||||| ||**-**|**-**|**-**|**-**|| ||**-**|**-**|**-**|**-**|| |**_Sub total_**|**0.00**|**0.00**|**0.00**|**0.00**|**0.00**| |**_Total payments_**
**_Net of receipts/(payments)_**
**A5 Transfers between funds**
**A6 Cash funds last year end**
**_Cash funds this year end_**|||||| ||**0.00**|**0.00**|**0.00**|**0.00**|**0.00**| ||||||| ||**25,000.00**|**0.00**|**0.00**|**25,000.00**|**0.00**| ||**-**|**-**|**-**|**-**|**-**| ||**-**|**-**|**-**|**-**|**-**| ||**25,000.00**|**0.00**|**0.00**|**25,000.00**|**0.00**| ||||||| |**Section B Statement o**|**f assets and**|**liabilities at**|**the end of t**|**he period**|| |**Categories**
Signed by one or two trustees on behalf
of all the trustees
Sign
None
**Details**
**Details**
None
Unrestricted grant pro
pharmaceutical comp
**B1 Cash funds**
**Details**
**B2 Other monetary assets**
**Details**
**_T_**
(agree balances wit
None
**B4 Assets retained for the**
**charity’s own use**
**B5 Liabilities**
**B3 Investment assets**
**Details**
None
Marc Lipman|**Details**||**Unrestricted**
**funds**
**to nearest £**|**Restricted**
**funds**
**to nearest £**|| ||Unrestricted grant pro
pharmaceutical comp|vided by
any.|**25,000**|**-**|**-**| ||||**-**|**-**|**-**| ||||**-**|**-**|**-**| ||**_T_**
(agree balances wit|**_otal cash funds_**
h receipts and payments
account(s))|**25,000.00**|**0.00**|**0.00**| ||||**OK**|**OK**|**OK**| ||**Details**||**Unrestricted**
**funds**
**to nearest £**|**Restricted**
**funds**
**to nearest £**|| ||None||**-**|**-**|**-**| ||||**-**|**-**|**-**| ||||**-**|**-**|**-**| ||||**-**|**-**|**-**| ||||**-**|**-**|**-**| ||||**-**|**-**|**-**| ||**Details**||**Fund to which**
**asset belongs**|**Cost (optional)**|| ||None|||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| ||**Details**||**Fund to which**
**asset belongs**|**Cost (optional)**|| ||None|||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| |||||**-**|**-**| ||**Details**||**Fund to which**
**liability relates**|**Amount due**
**(optional)**|| ||None|||**-**|| |||||**-**|| |||||**-**|| |||||**-**|| |||||**-**|| ||
Sign|ature|Print|Name|| ||||||Date of
approval| ||||Prof Mar|cLipman|| ||||||| |||1|||| |Marc Lipman (Oct 26, 2021 08:34 GMT+1)
|||||| CCXX R1 accounts (SS) 25/10/2021 Oct 26, 2021